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The ins and outs of osteopontin
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The continuous remodeling of progressing tumors demands non-physiologic production of extracellular matrix
(ECM) proteins. Among them, osteopontin (OPN) has been largely involved in tumor progression and metastasis. We
have recently discovered a new mechanism for OPN in the metastatic spread of mammary carcinoma providing local
immunosuppression at the seeding site.
Matricellular proteins are non-struc-
tural ECM proteins that regulate several
cellular processes such as cell adhesion and
migration, ECM deposition, cell survival,
and proliferation. All these physiological
functions are exploited by the neoplastic
clones for tumor growth and dissemina-
tion.1 A deregulated expression of matri-
cellular proteins is often detected in
tumors, where they can be produced by
both tumor cells and surrounding stromal
cells, but it is still unclear if their function
can be different depending from the
source. OPN (Spp-1) is one of the most
studied matricellular proteins and its con-
tribution to both primary tumor growth
and metastasis has been demonstrated in
several tumor types. Indeed, high expres-
sion of OPN has been correlated with
poor survival of cancer patients with dif-
ferent tumors and elevated OPN plasma
concentration is detected in patients with
metastatic tumors compared to normal
samples.2 Such pro-tumorigenic activity is
somehow contradictory with the original
description of OPN as a Th1-like cyto-
kine, promoting IL-12, while dampening
IL-10, production in macrophages.3
These data may suggest different activi-
ties for the same molecule when produced
by distinct cell types and indicate the need
of more in depth comprehension of the
molecular mechanisms behind OPN func-
tions in primary and metastatic tumor
microenvironment.
Using a spontaneously metastatic
mouse model of breast carcinogenesis, we
have recently dissected the role of OPN in
the metastatic process when produced by
the neoplastic clone or by host immune
cells, particularly myeloid cells.4 Combin-
ing OPN gene silencing of tumor cells,
and OPN-deficient mice we have demon-
strated that both tumor- and myeloid-
derived OPN contributes to metastatic
progression, through distinct and com-
mon mechanisms. Specifically, OPN pro-
duced by tumor cells, protect cells from
apoptosis in condition of anoikis, like in
blood stream, whereas OPN from myeloid
cells regulates their immunosuppressive
activity in the local metastatic niche.
These myeloid cells belong to the so-called
myeloid-derived suppressor cells (MDSC)
population, which, endowed with immu-
nosuppressive activity, expands along solid
tumor progression in most mouse tumor
models and in human cancers, contribut-
ing to both primary tumor growth and
metastasis.5,6 This suppressive population
comprises in the mouse two main subsets:
granulocytic and monocytic cells, express-
ing the Gr-1 marker at high (Gr-1high) or
low-intermediated Gr-1 (Gr-1 int-low)
level, respectively. These subsets show dif-
ferent suppressive capacity, with the
monocytic being generally more suppres-
sive than the granulocytic population.7
We have found that OPN is mainly
expressed by the monocytic subset in
which contributes to the suppressive activ-
ity via regulation of genes like arginase-1,
Stat3, and Il-6. Moreover, in the meta-
static lungs of mice deficient for OPN, the
more suppressive Gr-1int-low subset is
less expanded than in OPN-competent
hosts, rendering the local metastatic niche
less immunosuppressive (Fig. 1).
Notably we have found clinical correla-
tion to these findings detecting the pres-
ence of myeloid cells, with monocytoid
morphology, expressing OPN within lung
metastases of human ductal mammary
carcinomas. Such cells were mostly local-
ized in the stroma surrounding metastatic
foci suggesting a role in the local events
favoring the metastatic spreading.
In addition, the absence of OPN in
tumor-bearing mice was associated with a
decrease in number of regulatory T cells
(Treg) in the metastatic lungs, but, differ-
ently from MDSC, it had no effect on
their suppressive activity. Whether the
effect on Treg number depends on a cell-
intrinsic defect associated to OPN defi-
ciency or on “unfit” Spp1–/– MDSC
incapable of inducing Treg conversion,8 it
remains to be elucidated.
Further investigating the different roles
of OPN when produced by tumor and
myeloid cells, we have found a different
OPN cellular localization in tumor vs.
myeloid cells: while in tumor cells OPN is
mainly cytoplasmic localizing in the endo-
plasmic reticulum, in monocytic myeloid
cells it remains confined in specific spots
under the cellular membrane, and does
not localize in the ER, consistently with
the intracellular OPN (iOPN) form
recently reported in plasmocytoid DC
(pDC).9
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AUTHOR'S VIEW
Our finding is the first contribution
describing a role for iOPN in cancer,
shaping immunosuppression of lung met-
astatic niche via modulation of MDSC.
While the molecular mechanisms for
iOPN activities in pDC have been eluci-
dated,9,10 those behind MDSC-mediated
immunosuppression remain to be defined.
It would be interesting to investigate
whether such mechanisms use the same
molecular mediators as in pDC, i.e.,
iOPN association with MyD88 upon
TLR ligation. Most likely iOPN is the
product of an alternative translation start-
ing downstream the signal sequence, but
the cell type-specific factor determining
the choice of this alternative initiation of
translation, instead of the canonical AUG
site, remains unknown. Although, the
functional outcome of iOPN seems differ-
ent in pDC and MDSC in term of fueling
and dampening immune response, respec-
tively, a possible common trait points to a
program of “fitness in function” meaning
the production of IFNa in response to
viral infection in pDC and immune sup-
pression in MDSC, which are the main
functional specifications of these two cell
populations.
Deciphering the cell type-specific
mechanisms and the distinct, and even
opposite, activities in the different cells
and of the different forms of OPN, may
be critical for its potential therapeutic tar-
geting guiding the correct choice of the
specific approach: a neutralizing antibody
for selective depletion of sOPN maintain-
ing the function of iOPN, or other strate-
gies, such as RNA silencing, to block both
sOPN and iOPN?
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Figure 1. Schematic representation of OPN activities in tumor and monocytic myeloid cells and of
the effects of its downmodulation. Tumor cells mainly express the soluble form of OPN (sOPN) and
its downmodulation by means of gene silencing affects their ability to survive in anoikis condition,
such as in the lung blood stream; moreover OPN-silenced tumor cells produce less VEGF and IL-6,
two molecules involved in MDSC ﬁtness and suppressive activity; this in turn results in less suppres-
sive MDSC that produce lower amounts of arginase 1. On the other hand, OPN in monocytic MDSC
(M-MDSC) is mainly in its intracellular form (iOPN) and it is involved in maintaining their suppressive
activity: when MDSC are not able to produce OPN, as in mice deﬁcient for the protein (spp1–/–
mice), their expression of immunosuppressive genes, such as arginase1 and Stat3, is downmodu-
lated and, in turn, they are less competent in suppressing CD8C and CD4C T cell proliferation; con-
comitantly, the number of regulatory T cells is lower in spp1–/–mice.
e978711-2 Volume 4 Issue 3OncoImmunology
